Lifemd, INC Form 4 insider transactions

Justin Schreiber, Chairman and CEO of LifeMD, Inc., reports the sale of 50,000 shares of common stock at a weighted average price of $7.7808.

Maria E. Stan, Chief Accounting Officer of LifeMD, Inc., reports the acquisition of common stock through vesting of restricted stock units and performance stock.

Nicholas Alvarez, Chief Acquisition Officer of LifeMD, reports the acquisition of 75,000 common shares and disposal of 580,000 shares on March 31, 2025, following the vesting of performance stock.

Dennis Wijnker, Chief Technology Officer of LifeMD, Inc., reports a transaction involving the acquisition and disposal of common stock.

Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc., reports acquiring 30,000 shares of common stock on March 31, 2025, due to the vesting of performance stock.

LifeMD's Chief Financial Officer, Marc David Benathen, reports acquiring 75,000 shares of common stock on March 31, 2025.

Eric Harold Yecies, Chief Legal Officer & GC of LifeMD, Inc., reports the acquisition of 48,750 shares of common stock due to vesting on March 31, 2025.

LifeMD CEO Justin Schreiber reported gifting shares of common stock to his children and Schreiber Holdings LLC.

LifeMD's Chief Marketing Officer, Jessica Friedeman, recently sold 30,000 shares of common stock at an average price of $5.6555.

Maria E. Stan, Chief Accounting Officer of LifeMD, Inc., reports acquiring 40,000 shares of common stock through grants.

Nicholas Alvarez, Chief Acquisition Officer of LifeMD, Inc., reports the acquisition of 100,000 common shares and disposal of 505,000 shares on March 7, 2024, following the vesting of performance stock.

LifeMD's Chief Innovation Officer, Stefan Galluppi, reports acquiring 30,000 shares of common stock on March 7, 2025, as part of a performance stock grant.

LifeMD's CFO, Marc David Benathen, reports acquiring 87,000 shares of common stock on March 7, 2025, through a grant of performance stock.

Jessica Friedeman, Chief Marketing Officer of LifeMD, reports the acquisition of 50,000 shares of common stock via a grant that vested on March 7, 2025, and the disposal of 200,000 shares.

LifeMD's Chief Legal Officer & GC, Eric Harold Yecies, reports acquiring 50,000 shares of common stock on March 7, 2025, as part of a performance stock grant.

Dennis Wijnker, Chief Technology Officer of LifeMD, Inc., reports acquiring 25,000 shares of common stock on March 7, 2025, as part of a performance stock grant.

Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc., reports the acquisition of 60,000 common shares and disposal of 1,644,800 common shares held indirectly through American Nutra Tech, LLC.

LifeMD CEO Justin Schreiber sold 50,000 shares of common stock at an average price of $7.5524 on February 14, 2025.

LifeMD CEO Justin Schreiber sold 25,000 shares of common stock at a weighted average price of $5.1867 per share on January 2, 2025.

LifeMD director Joan LaRovere acquired 9,685 shares of common stock through a grant under the company's 2020 Equity and Incentive Plan.

LifeMD director Joseph DiTrolio reported the acquisition of restricted shares and an update to his beneficial holdings, including shares from a previous option exercise.

LifeMD director Roberto Simon acquired a total of 60,810 shares of common stock through the vesting of restricted shares on December 2, 2024.

LifeMD director John R. Strawn Jr. acquired a total of 57,289 shares of common stock through vesting of restricted shares on December 2, 2024.

LifeMD CEO Justin Schreiber sold 25,000 shares of common stock at an average price of $6.517, while also acquiring 200,000 shares directly.

Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc., purchased 3,000 shares of common stock at an average price of $4.93 on September 11, 2024.

Dennis Wijnker, Chief Technology Officer of LifeMD, Inc., filed a Form 4 detailing changes in his beneficial ownership of company stock, including the cancellation of stock options in exchange for restricted shares.

Piyush Jindal, a director and consultant at LifeMD, Inc., acquired 24,835 shares of common stock on July 17, 2024.

Director Calum Archibald MacRae acquired 16,500 shares of LifeMD, Inc. common stock on April 26, 2024.

Naveen Bhatia, a director and consultant at LifeMD, Inc., reported acquiring 500 shares of common stock on April 4, 2024.

LifeMD's General Counsel & CCO, Eric Harold Yecies, reports acquiring 56,250 shares of common stock due to performance share vesting.